Shionogi & Co.,Ltd. Logo

Shionogi & Co.,Ltd.

A research-driven pharmaceutical firm creating drugs, diagnostics, and devices for global health.

4507 | T

Overview

Corporate Details

ISIN(s):
JP3347200002
LEI:
Country:
Japan
Address:
大阪市中央区道修町3丁目1番8号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Shionogi & Co., Ltd. is a research-driven pharmaceutical company focused on the discovery, development, manufacturing, and marketing of pharmaceuticals, diagnostic reagents, and medical devices. With a history of over 140 years, the company is dedicated to creating innovative products and services that deliver value to patients and society globally. As a drug discovery-based organization, Shionogi leverages its robust research and development pipeline to address unmet medical needs and contribute to the health of people worldwide.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-07 03:07
Registration Form
確認書
Japanese 8.9 KB
2025-11-07 03:05
Interim Report
半期報告書-第161期(2025/04/01-2026/03/31)
Japanese 327.3 KB
2025-09-25 08:53
M&A Activity
訂正臨時報告書
Japanese 48.0 KB
2025-06-19 09:24
Post-Annual General Meeting Information
臨時報告書
Japanese 30.7 KB
2025-06-19 09:14
Governance Information
内部統制報告書-第160期(2024/04/01-2025/03/31)
Japanese 30.2 KB
2025-06-19 09:12
Registration Form
確認書
Japanese 8.9 KB
2025-06-19 09:10
Annual Report
有価証券報告書-第160期(2024/04/01-2025/03/31)
Japanese 2.5 MB
2025-06-19 08:07
M&A Activity
公開買付報告書
Japanese 41.6 KB
2025-06-19 06:40
Major Shareholding Notification
大量保有報告書
Japanese 61.0 KB
2025-06-18 08:49
Share Issue/Capital Change
臨時報告書
Japanese 41.9 KB
2025-06-04 08:39
M&A Activity
訂正公開買付届出書
Japanese 258.4 KB
2025-05-28 08:38
M&A Activity
訂正公開買付届出書
Japanese 262.0 KB
2025-05-08 05:52
M&A Activity
公開買付届出書
Japanese 530.2 KB
2025-05-07 09:12
M&A Activity
臨時報告書
Japanese 50.3 KB
2024-11-08 02:44
Interim Report
確認書
Japanese 9.0 KB

Automate Your Workflow. Get a real-time feed of all Shionogi & Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Shionogi & Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Shionogi & Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

NEOGEN CORP Logo
Provides diagnostic tests and genomics services for food, animal, and agricultural safety.
United States of America
NEOG
NEOGENOMICS INC Logo
Provides precision oncology testing for cancer diagnostics, therapy guidance, and research.
United States of America
NEO
NeoImmuneTech, Inc. Logo
Develops NT-I7, a T cell-amplifying immunotherapy for cancer and infectious diseases.
United States of America
950220
NEONC TECHNOLOGIES HOLDINGS, INC. Logo
Developing intranasal drug delivery to treat brain cancer & CNS diseases by crossing the BBB.
United States of America
NTHI
Neumora Therapeutics, Inc. Logo
Developing data-driven precision medicines for neuropsychiatric and neurodegenerative disorders.
United States of America
NMRA
Neuphoria Therapeutics Inc. Logo
Develops novel ion channel modulators for treating neuropsychiatric disorders like anxiety & PTSD.
United States of America
NEUP
NEUROCRINE BIOSCIENCES INC Logo
Develops therapies for neurological, neuroendocrine, and neuropsychiatric disorders.
United States of America
NBIX
Neurogene Inc. Logo
Developing genetic medicines using gene therapy for rare and devastating neurological diseases.
United States of America
NGNE
NeuroSense Therapeutics Ltd. Logo
Developing combination therapies for neurodegenerative diseases, with a focus on ALS.
United States of America
NRSN
NewAmsterdam Pharma Co N.V. Logo
Developing oral LDL-lowering therapies for high-risk cardiovascular disease patients.
United States of America
NAMS

Talk to a Data Expert

Have a question? We'll get back to you promptly.